SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is seeing increased volatility as investors react to reports of a significant VMware security vulnerability, even as community sentiment remains divided between short-term FUD and long-term institutional accumulation. Discussion is heavily focused on whether this drawdown represents a genuine shift in the AI hardware investment thesis or simply an overreaction exacerbated by options expiration and broader semiconductor sector weakness.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist Inc. is experiencing significant market interest and price appreciation as investors anticipate further patent settlements following a landmark cross-license agreement with Samsung. The community is actively discussing the stock's short squeeze potential, driven by heavy short interest and the prospect of upcoming legal resolutions with major industry players.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The iShares Russell 2000 ETF is currently experiencing heightened engagement as traders actively debate its recent push toward all-time highs and the potential for a technical breakout. Community discussion is split between bullish momentum traders anticipating further gains and skeptical market participants closely monitoring put/call volume for signs of institutional hedging or an impending pullback.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors weigh strong institutional accumulation and positive developments regarding its Texas data-center pipeline against recent price volatility and regulatory scrutiny in the region. The community remains divided, with bulls highlighting the stock's long-term potential as a tier-one infrastructure operator while others express frustration over technical pressure and broader sector sell-offs.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is seeing high retail interest as investors speculate on a potential short squeeze ahead of Q2 earnings, with many pointing to heavy short interest and a low float as catalysts for a violent upside move. Community sentiment is divided, however, as discussions are dominated by debates over the company's convertible note structure, dilution concerns, and intense skepticism regarding management's communication and contract execution.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is generating significant community interest as investors weigh its role in the domestic drone supply chain against recent price volatility and concerns regarding dilution. The discourse is heavily focused on the potential for institutional and government-backed contracts, with active debate regarding whether the stock's recent performance represents a structural opportunity for long-term growth or a speculative play prone to market-wide sector resets.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to the expiration of the TDAPA reimbursement period and the company's recent expansion into the LDO market, including a new multi-year supply agreement with DaVita. Community discussion is sharply divided between bulls highlighting strong revenue growth and institutional accumulation, and skeptics voicing concerns over future revenue cliffs and management's communication strategy.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a Q4 BLA submission and institutional accumulation that has driven the share price to 18-month highs. The community is actively discussing the stock's clinical potential, the significance of high institutional ownership, and anticipation surrounding upcoming investor conferences and data readouts.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors digest a Wells Fargo analyst's price target hike, while the community intensely debates its position relative to AI hardware peers like Super Micro Computer. Discussion is heavily focused on the stock's role in the resilient AI infrastructure supercycle, with retail sentiment largely split between bullish enthusiasm for its server-driven upside and skeptical concerns regarding valuation and sector-wide volatility.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

Boost Run Inc. is currently attracting intense investor attention following a strong earnings report that highlighted massive contracted revenue growth and a strategic expansion of GPU compute capacity. While bullish sentiment is fueled by the company's status as an NVIDIA Preferred Cloud Partner and a significant multi-billion dollar contract pipeline, the stock is experiencing high volatility as traders debate the potential impact of an upcoming warrant redemption deadline and broader market cooling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. Throughout the first half of...

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646...

Community Health Q2 Loss Wider Than Expected, 2026 View Lowered

CYH posts a wider-than-expected Q2 loss as revenues fall and the company cuts its 2026 revenue, EBITDA and earnings outlook.

UnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 Outlook

UNH beats Q2 earnings estimates on lower medical costs and stronger Optum Insight, then raises its 2026 EPS and cash flow outlook.

Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer

(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) announced the retirement of Chief Medical Officer and Head of Research and Drug Development Michael Shetzline and the appointment of Jeffrey Silber as his successor. Silber will oversee Research and Drug Development,
Regulatory A...

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael...

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

$IRWD Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.31 up 106.67% YoY
• Reported revenue of $113.04M up 32.62% YoY
• Ironwood Pharmaceuticals raised its 2026 full-year financial guidance, now expecting U.S. LINZESS net sales of $1.15 to $1.20 billion, total revenue of $460 to $485 million, and adjusted EBITDA greater than $310 million.

Ironwood Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?

Equity

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info